BeNeLuxBelgiumNetherlandsLuxembourg

Antithrombrotic Mab enters clinical tests

14.08.2008

Belgian Ablynx N.V. (Ghent) has started a Phase Ib safety and dose-finding study of ALX-0081, an antithrombotic antibody fragment that targets von Willebrand factor (vWF).

BeNeLuxBelgiumNetherlandsLuxembourg

16.12.2011

Mechelen - Galapagos NV confirms its status as one of Europe best drug discovery companies. The Belgian biotech received €4 million as the first milestone payments from French Servier for the discovery of new targets for...

BeNeLuxBelgiumNetherlandsLuxembourg

15.12.2011

Munich/Groningen/Penzberg – For ten years, the application of image-guided surgery with tumour-specific fluorescent dyes has been limited to animal studies, because no one could predict safety or bio­distribution of such targeted...

BeNeLuxBelgiumNetherlandsLuxembourg

02.12.2011

Zwijnaarde/Rotterdam – In vivo camelid antibody specialist arGEN-X BVBA has baged €27.5 million of fresh capital for development of its preclinical monoclonal antibody pipeline. The round B financing of the 3 year-old company,...

BeNeLuxBelgiumNetherlandsLuxembourg

28.11.2011

Brussels/Ghent – Belgian researchers have demonstrated that tumour cells secrete the angiogenesis factor VEGF to create a microenvironment that fosters proliferation of cancer stem cells. In mice with squamous cell carcinoma,...

BeNeLuxBelgiumNetherlandsLuxembourg

23.11.2011

Mechelen – Belgian drugmaker Galapagos NV has reported impressive results of a proof-of-concept trial with its oral janus kinase 1 blocker GLPG0634 + Methothrexate in patients with active rheumatoid arthritis. In the 24 patients...

BeNeLuxBelgiumNetherlandsLuxembourg

18.11.2011

Naarden – Enzyme replacement therapies specialist Oxyrane NV raised €20 million in a series D round of financing. The therapies are designed to treat lysosomal storage diseases, a class of more than forty rare inherited diseases....

BeNeLuxBelgiumNetherlandsLuxembourg

14.11.2011

Hilden/Venlo – Sample and assay technologies provider Qiagen N.V. is set to eliminate about 10% of its current global workforce of 3,800 employees. The company says the cuts are one result of implementing a project aimed at...

BeNeLuxBelgiumNetherlandsLuxembourg

09.11.2011

New York/Ghent - Big brother is gone. Belgian biotech Ablynx regained the rights for nanobodies targeting TNF-alpha from Pfizer. The US- pharma outfit decided it did't want ATN-103, even though it met its goal in a mid-stage...

BeNeLuxBelgiumNetherlandsLuxembourg

25.10.2011

Amsterdam - The second blow could be the ultimate one. Amsterdam Molecular Therapeutics received a second negative opinion for Glybera to treat lipoprotein lipase (LPL) deficiency. The European Medicines Agency's (EMA) Committee...

BeNeLuxBelgiumNetherlandsLuxembourg

13.10.2011

Bilthoven – The current impact of hospital acquired infections with multi-resistant bugs is lower than suggested by startling news articles. According to a study of Dutch researchers, bloodstream infections caused by...

Displaying results 11 to 20 out of 304

< Previous 11-20 Next >

© 2007-2015 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-benelux/browse/1/article/antithrombrotic-mab-enters-clinical-tests.html

Whitepaper

Product of the week

Products

Events

All Events

Stock list

All quotes

TOP

  • SCANCELL HOLDINGS (UK)29.25 GBP7.93%
  • CELLECTIS (F)32.30 EUR7.31%
  • ALMIRALL (E)17.87 EUR7.26%

FLOP

  • TRANSGENE (F)3.99 EUR-14.56%
  • BAVARIAN NORDIC (D)39.72 EUR-5.61%
  • EUROFINS SCIENTIFIC (F)255.00 EUR-5.39%

TOP

  • VERONA PHARMA (UK)5.20 GBP24.7%
  • PROTHENA PLC (IE)52.67 USD23.4%
  • DBV Technologies (F)51.87 EUR21.8%

FLOP

  • NORDIC NANOVECTOR (N)26.90 NOK-23.4%
  • NEUROVIVE PHARMACEUTICAL AB (S)20.10 SEK-23.3%
  • OREXO (S)68.00 SEK-22.5%

TOP

  • ADOCIA (F)67.19 EUR384.1%
  • 4SC (D)4.52 EUR334.6%
  • WILEX (D)3.64 EUR333.3%

FLOP

  • CHRONTECH PHARMA (S)0.02 SEK-75.0%
  • ACTIVE BIOTECH (S)8.60 SEK-70.1%
  • NEOVACS (F)1.12 EUR-67.2%

No liability assumed, Date: 01.07.2015

Current issue

All issues